something perhaps afoot, page-3

No idea, but both are small cancer R&D companies and now there is one important person who straddles both. SBP have said they are looking for deals. ACU has done several in the past. There would have to be discussions going on. Maybe they will go nowhere. Opara would need to be onside though.

Not necessarily relevant to the above, ACU must have some promise for Elliott to have joined.